Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients

Due to rare but major adverse reactions to the AstraZeneca adenoviral ChAdOx1-S-nCoV-19 vaccine (ChAd), German health authorities recommended adults under 60 who received one dose of ChAd, to receive a second dose of the BioNTech mRNA BNT162b2 vaccine (BNT) as a booster. Studies in the general popul...

Full description

Bibliographic Details
Main Authors: Chang Chu, Anne Schönbrunn, Dorothea Fischer, Yvonne Liu, Johann-Georg Hocher, Jutta Weinerth, Kristin Klemm, Volker von Baehr, Bernhard K. Krämer, Saban Elitok, Berthold Hocher
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
heterologous vaccination
homologous vaccination
AstraZeneca adenoviral ChAdOx1-S-nCoV-19 vaccine
BioNTech mRNA BNT162b2 vaccine
immune response
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1187880/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1187880/full

Similar Items